Skip to content

Erasca, Inc. ERAS Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Pfizer logo
PfizerPFE
10.6%
Amgen logo
AmgenAMGN
101.3%-4.4pp
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-76.7%-923pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-38.4%-10.5pp

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s return on equity?
Erasca, Inc. (ERAS) reported return on equity of -69.9% in Q1 2026.
How has Erasca, Inc.'s return on equity changed year-over-year?
Erasca, Inc.'s return on equity decreased by 52.5% year-over-year, from -45.8% to -69.9%.
What is the long-term trend for Erasca, Inc.'s return on equity?
Over 3 years (2022 to 2025), Erasca, Inc.'s return on equity has grown at a -15.9% compound annual growth rate (CAGR), from -55.9% to -33.3%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.